A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants

Mostrar otras versiones (1)

vaccines include mRNA-containing lipid nanoparticles or adenoviral vectors that encode the SARS-CoV-2 Several vaccines have been introduced to combat the coronavirus infectious disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Linglei, Driedonks, Tom A.P., Jong, Wouter S.P., Dhakal, Santosh, van den Berg van Saparoea, H. Bart, Sitaras, Ioannis, Zhou, Ruifeng, Caputo, Christopher, Littlefield, Kirsten, Lowman, Maggie, Chen, Mengfei, Lima, Gabriela, Gololobova, Olesia, Smith, Barbara, Mahairaki, Vasiliki, Richardson, M. Riley, Mulka, Kathleen R., Lane, Andrew P., Klein, Sabra L., Pekosz, Andrew, Brayton, Cory F., Mankowski, Joseph L., Luirink, Joen, Villano, Jason S., Witwer, Kenneth W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820665/
https://www.ncbi.nlm.nih.gov/pubmed/35132418
http://dx.doi.org/10.1101/2021.06.28.450181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820665/
https://www.ncbi.nlm.nih.gov/pubmed/35132418
http://dx.doi.org/10.1101/2021.06.28.450181

Ejemplares similares